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Methoxysubstituted 5,6-dihydro-indolo[2,l-a]isoquinolines with a methyl 
(2b-f) or a formyl group at C-12 (4a-f) and 12,12-dimethylisoquinolinium 
salts (3b-f) were synthesized and tested for cytostatic activity in vitro. The 
tetramethoxy-indoloisoquinoline 4f was the most active derivative in the P 
388 Dl leukemia cell line, whereas compounds with two methoxy groups 
(4a, 4b) were more potent against the M D A - M B 231 mammary tumor 
cells. The tetraacetoxy-12-formyl-5,6-dihydro-indoloisoquinoline 9 has 
proven to be active in both cell lines (T/C = 5 %). In vivo it increased the 
life span of mice with P 388 leukemia (T/C = 133 %). The acetates 7 and 8 
exhibited binding affinities for the estrogen receptor, but did not exert a se-
lective action on hormone-dependent M C F - 7 cells. 
In 12-Stellung substituierte Indolo[2,l-a]isochinoline als östrogenrezep-
toraffine Cytostatika 
Methoxysubstituierte 5,6-Dihydro-indolo[2,l-a]isochinoline mit einer 
Methyl- (2b-f) oder Formylgruppe an C-12 (4a-f), sowie die 12,12-Dime-
thylisochinoliniumsalze 3b-f wurden synthetisiert und auf cytostatische 
Wirksamkeit in vitro getestet. Das Tetramethoxyindoloisochinolin 4f war 
die aktivste Substanz an P 388 D^Leukaemiezellen, während Verbindun-
gen mit zwei Methoxygruppen (4a, 4b) an der menschlichen M D A - M B 
231-Zellinie wirksamer waren. Das Tetraacetoxy-12-formyl-5,6-dihydro-
indoloisochinolin 9 war an beiden Zellinien aktiv (T/C = 5 %). In vitro 
verlängerte 9 die Überlebenszeit von Mäusen mit P 388-Leukaemie (T /C 
= 133 %). Die Acetate 7 und 8 zeigten Affinität zum Östrogenrezeptor, 
aber bewirkten keine selektive Hemmung an hormonabhängigen M C F - 7 
Zellen. 
In a previous paper we described the synthesis of a number of methoxy-
substituted indolo[2,l-a]isoquinolines and their dihydro derivatives 
la-P). Their cytostatic activity was too low for the intended development 
of cytostatic agents binding to the estrogen receptor. 
Therefore, we tried to increase their activity by introduc-
tion of an additional substituent in position 12 of the tetra-
cycle. Two different substituents were considered: the methyl 
group in order to increase the lipophilicity and a formyl 
group to decrease the electron density at the nitrogen. A fur-
ther step was the conversion of the indoloisoquinolines to 
quaternary salts. A l l of the compounds were tested for their 
cytostatic activity in vitro using M D A - M B 231 mammary 
tumor cells and P 388 D x leukemia cells. Since a prerequisite 
for the binding to the estrogen receptor is the presence of hy-
droxy or acetoxy groups in the aromatic rings, the methoxy 
groups of some derivatives were cleaved. After conversion to 
the acetates, their binding affinities for the estrogen receptor 
(ER) were determined. 
Chemistry 
The methoxy substituted 12-methyl-5,6-dihydro-indo-
lo[2,l-alisoquinolines 2b-f were obtained by reacting lb-f 1 } 
with an excess of C H 3 I at 90-93° in a sealed tube. Increasing 
the temp, to 110° led to the quaternary isoquinolinium salts 
3b-f. The formation of quaternary N-methyl compounds 
can be ruled out by ^ - N M R spectroscopy. The spectra 
showed only one singulett for the two methyl groups at C-12 
at 5 1.85. The formyl group in compound 4a-f was introdu-
ced in la-f by a Vilsmeier-Haack reaction using D M F / 
P€)G1|. The regiospecific attack at position 12 was confir-
med by spectroscopy. In the ^ - N M R spectra the vinyl pro-
ton has disappeared and the IR-spectra showed a carbonyl 
vibration at 1635 cm - 1 , a value characteristic for vinylogous 
amides2). Compounds 2f and 4f were dehydrogenated to the 
aromatic indolo[2,l-a]isoquinoiines 5 and 6 using Pd/C. For 
1-4 R 1 R 2 R 3 
a H H O C H 3 
b H O C H 3 H 
c H O C H 3 O C H 3 
d 0 C H 3 H O C H 3 
e O C H 3 OCH3 H 
f OCH3 O C H 3 OCH3 
0 
6 R = CHO 8 R 1 = R 2 = H, R 3 = CHO 
9 R1 = R2 = OCOCH3, R 3 = CHO 
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the determination of the binding affinities of 2b, 4b and 4f for 
the ER, the methoxy groups were cleaved by BBr 3 . The resul-
ting phenols were converted to the acetates 7, 8, and 9, be-
cause of their better stability. 
Cytostatic Activity and Receptor Affinity 
Three cell lines were used for the determination of cytosta-
tic activity: P 388 Dl cells deriving from a mouse leukemia, 
hormone-independent M D A - M B 231 and hormone-depen-
dent M C F - 7 mammary tumor cells of human origin. A l l of 
the new indoloisoquinolines were tested for cytostatic effects 
at a concentration 10~5 molar. The inhibition of cell growth 
was measured by cell counting and 3H-thymidine labeling. 
Like the starting 5,6-dihydro-indolo[2,l-a]isoquinolines la-f 
the 12-methyl derivatives 2b-f showed no significant inhibi-
tory effect in both cell lines. The aromatic compound 5 was 
also devoid of cytostatic activity. In the series of the dime-
thyl-5,6-dihydro-indoloisoquinolinium salts 3b-f, one com-
pound (3b) was active against P 388 Dj cells (T/C = 45 %) 
(Table 1). The introduction of a formyl group into position 
12 led to a marked increase in cytostatic activity both in P 
Tab. 1: Effect of 3 b - f on the Growth of M D A - M B 231 and P 388 
D x Cells 
P 388 DJ M D A - M B 231 
Cel l no. 3 H-thymidine Cel l no. 3 H-thymidine 
Compound 3 ^ % T / C b ) 
incorp. 
% T /C 1 3 ) % T / C b > 
incorp. 
% T / C 6 ) 
3b 45 45 87 55 
3bc> 85 85 
3c 85 75 90 92 
3d 85 83 90. 91 
3e 73 73 90 90 
3f 75 67 99 97 
a) Concentration 10 M . 
b) % T / C = test compound/control, X 100; mean of three tests with 
six dishes or test tubes. 
c) Concentration 1 0 ~ 6 M . 
Tab. 2: Effect of 12-Formyl-indoloisoquinolines 4a - f , 6, 8 and 9 on 
the Growth of M D A - M B 231 and P 388 Dx Cells 
P 388 D i M D A - M B 231 
Cell no. 3 H-thymidine Cell no. 3 H-thymidine 
Compound 3 ) 
incorp. incorp. 
% T / C b ) % T / C b ) % T / C b ) % T / C b ) 
4a 52 25 25 6 
4b 52 48 24 2 
4c 78 25 53 7 
4d 70 39 69 12 
4e 25 10 35 4 
4f 20 7 64 4 
4fc) 80 50 
6 70 86 20 20 
8 88 82 40 2 
9 5 0 10 0 
9C) 23 23 40 30 
9 d ) 63 80 
9 e ) 82 91 
a) Concentration 1 0 ~ 5 M . 
b) % T / C = test compound/control, X 100; mean of three tests wi th 
six dishes or test tubes. 
c) Concentration 5 X 1 0 ~ 6 M . 
d) Concentration 10 " 6 M . 
e) Concentration 5 X 1 0 " 7 M . 
388 D x leukemia and M D A - M B 231 mammary tumor cells 
(Table 2). In all cases the inhibition of the 3H-thymidine in-
corporation exceeded the effect on cell number. The tetrame-
thoxy-indoloisoquinoline 4f was the most active methoxy de-
rivative against leukemia cells, whereas compounds with two 
methoxy groups (4a, 4b) were more potent in mammary tu-
mor cells. Differences between the two cell lines were also ob-
served with 6 and 8. 
Since the methoxy compounds generally do not bind to the 
estrogen receptor, we converted in a preliminary study three 
derivatives to the corresponding acetates 7-9. In order to 
prove that this conversion is not accompanied by a loss of cy-
tostatic activity we tested compound 9 in both hormone-in-
dependent cell lines. Interestingly, the acetate 9 was more ac-
tive than the corresponding methoxy derivative 4f (Table 2). 
The binding affinities of 7-9 for the estrogen receptor were' 
measured by a competitive binding assay with [ 3H]17ß-
estradiol. Calf uterine cytosol was used as receptor source 
and the dextran coated-charcoal (DCC) method was applied. 
The relative binding affinities (RB A) are given as the ratio of 
the molar concentrations of 17ß-estradiol and indoloisoqui-
noline required to decrease the receptor bound radioactivity 
by 50 %, multiplied by 100. Only compounds 7 (RBA = 0.2) 
and 8 (RBA = 0.4) exhibited a moderate receptor affinity, 
whereas the tetraacetate 9 did not bind to the receptor. This 
observation is in accordance with results obtained with 
2-phenylindoles3). 
The two derivatives with binding affinity for the estrogen 
receptor were tested for specific action against estrogen re-
ceptor positive human M C F - 7 mammary tumor cells. No 
improvement of cytostatic activity was found in comparison 
to hormon-independent cells. Compound 7 showed no inhibi-
tory effect, whereas 8 inhibited the growth of M C F - 7 cells at 
10 - 5 M by 60 % (cell number) and 83 % ([3H]thymidine in-
corporation), respectively. The strong cytostatic effect of 9 in 
vitro prompted us to determine the antitumor activity in vivo 
using the P 388 leukemia of the mouse. At a dose of 40 mg/kg, 
the increase of life span was 33 %. This value is above the limit 
set by the N C I for cytostatic activity4). 
Tab. 3: Effect of 9 on the Growth of P 388 Leukemia in vivo 
Compound 
dose 3) 
(mg/kg) 
Change of 
body weight b ) 
( T - C ) ; ( g ) 
Survival t ime c ) 
median range 
(d) (d) % T / C d ) 
9 10 - 0 . 9 10 9 - 1 2 111 
20 - 0 . 4 11 10 -14 122 
40 0.0 12 11 -13 133 
control — — 9 9 - 1 0 -
cis-DDP e ) 4 1.5 21 1 8 - 2 6 213 
a-d) See exp. part. 
e) cis-diammine-dichloro-platinum-(II). 
Discussion 
The structure activity studies of a number of substituted 
indolo[2,l-a]isoquinolines revealed, that only the introduc-
tion of a formyl group into position 12 leads to derivatives 
with a strong cytostatic activity against P 388 D x murine leu-
kemia and M D A - M B 231 human mammary tumor cells. For 
derivative 9 this effect was confirmed in vivo using the P 388 
leukemia of the mouse. Since Jthe aim of these studies is the 
development of cytostatic agents binding to the estrogen re-
ceptor three derivatives were converted into the acetates. 
Their binding affinities to the estrogen receptor were presu-
mably too low to exert a selective action on estrogen sensitive 
human M C F - 7 tumor cells. 
The authors thank C. Braun and M. Beer for technical assistance and 
the Deutsche Forschungsgemeinschaft (SFB 234) for financial support. 
Experimental Part 
Melting points: Büchi 510 apparatus, uncorrected. - Elemental analyses: 
Mikroanalytisches Laboratorium, University of Regensburg. - IR-spec-
tra: Beckman Acculab 3, K B r . - * H - N M R spectra: Varian E M 360 L , Va -
rian E M 390 or Bruker W M 250, C D C 1 3 , T M S as internal standard, 60 
M H z , if not stated otherwise. UV-spectra: Uvikon 810 Kontron. - Mass 
spectra: Varian M A T C H 5 . - Column Chromatography (CC) : Kieselgel 
60 (Merck). - Temp, in °C. 
General Procedure for the Synthesis of 5,6-Dihydro-l 2-methyl-indolo- . 
[2,1-alisoquinolines 2b-f 
5,6-Dihydro-methoxy-indoloisoquinoline (1.0 mmol) in 2.5 ml absol. 
M e O H and 2.5 ml C H 3 I was heated in a sealed tube to 90-93° for 3 h. Af-
ter cooling, the solvent was removed and the residue was purified by C C 
( S i 0 2 ; C H 2 C 1 2 ) . Recrystallization from E t O H yielded colorless crystals. 
The yields were between 50 and 60 %. 
5,6-Dihydro-3,9-dimethoxy-l2-methyl-indolo/2,1 -alisoquinoline (2b) 
M . p. 105-106°. - C 1 9 H 1 9 N O z (293.3) Calc. C 77.8 H 6.50 Found C 77.3 
H 6.56. - ^ - N M R : 5 (ppm) = 2.57 (s; 3H, - C H 3 ) , 3.09 (t; J = 7 H z , 2 H , 
- C H 2 - ) , 3.86 (s; 3 H , - O C H 3 ) , 3.9 (s; 3H, - O C H 3 ) , 4.14 (t; J = 7 H z , 2 H , 
- C H 2 - ) , 6.67-7.0 (m; 4 H , A r H ) , 7.45 (d; J = 9 H z , 1H, A r H ) , 7.75 (d; J = 
9 H z , 1H, A r H ) . - M S : m/z = 293 (100 %, M+-), 278 (84 %, *263.76). -
U V ( C H 3 C N ) : I max (log e) = 346 (4.39), 331 (4.45), 263 (4.26) nm. 
5,6-Dihydro-3,9,10-trimethoxy-l2-methyl-indolo/2,1-alisoquinoline (2c) 
M . p. 174°. - C 2 0 H 2 1 N O 3 (323.4) Calc. C 74.3 H 6.55 Found C 74.7 
H 6.70. - * H - N M R (90 M H z ) : 5 (ppm) = 2.55 (s; 3 H , - C H 3 ) , 3.08 (t; J = 
7 H z , 2 H , - C H 2 - ) , 3.85 (s; 3 H , - O C H 3 ) , 3.97 (s; 6 H , - O C H 3 ) , 4.13 (t; 
J - 7 Hz , 2 H , - C H 2 - ) , 6.79 (s; 1H, A r H ) , 6.84 (s; 1H, A r H ) , 6.90, 7.74 
( A B ; J = 9 Hz , 2 H , A r H ) , 7.03 (s; 1H, A r H ) . 
5,6-Dihydro-2,3,10-trimethoxy-l2-methyl-indolo/2,1-a/isoquinoline (2d) 
M . p. 142°. - C 2 0 H 2 1 N O 3 (323.4) Calc. C 74.3 H 6.55 Found C 74.1 
H 6.35. - ' H - N M R (90 M H z ) : 5 (ppm) = 2.6 (s; 3 H , - C H 3 ) , 3.05 (t; J = 7 
H z , 2 H , - C H 2 - ) , 3.86 (s; 3 H , - O C H 3 ) , 3.92 (s; 3 H , - O C H 3 ) , 3.96 (s; 3 H , 
- O C H 3 ) , 4.15 (t; J •= 7 Hz , 2 H , - C H 2 - ) , 6.73-7.1 (m; 4 H , A r H ) , 7.34 (s; 
1H, A r H ) . 
5,6-Dihydro-2,3,9-trimethoxy-l2-methyl-indolo/2,1-a/isoquinoline (2e) 
M . p. 150°. - C 2 0 H 2 1 N O 3 (323.4) Calc. C 74.3 H 6.55 Found C 74.5 
H 6.40. - *H N M R : 5 (ppm) = 2.59 (s; 3 H , - C H 3 ) , 3.05 (t; J = 7 H z , 2 H , 
- C H 2 - ) , 3.88 (s; 3 H , - O C H 3 ) , 3.93 (s; 3 H , - O C H 3 ) , 3.99 (s; 3 H , 
- O C H 3 ) , 4.16 (t; J = 7 H z , 2 H , - C H 2 - ) , 6.76-6.86 (m; 3H, A r H ) , 7.40 (s; 
1H, A r H ) , 7.47 (d; J = 9 H z , 1H, A r H ) . 
5,6-Dihydro-2,3,9,10-tetramethoxy-l 2-methyl-indolo/2,1-a/isoquinoline 
(20 
M . p. 216-217° - C 2 1 H 2 3 N 0 4 ( 3 5 3 . 4 ) C a l c . C 71.4 H 6.55 FoundC 71.0 
H 6.72. - * H - N M R (90 M H z ) : 8 (ppm) = 2.56 (s; 3 H , - C H 3 ) , 3.05 (t; J -
7 Hz , 2 H , - C H 2 - ) , 3.92 (s; 12H, - O C H 3 ) , 4.07 (t; J - 7 H z , 2 H , - C H 2 - ) , 
6.7 (s; 2 H , A r H ) , 6.93 (s; 1H, A r H ) , 7.27 (s; 1H, A r H ) . 
General Procedure for the Synthesis of 5,6-Dihydro-l 2,12-dimethyl-
indolo[2,l-a/isoquinolinium Iodides 3b-f 
The isoquinolinium salts were prepared in the same way as described for 
the monomethyl compounds, only the reaction temp, was raised to 110° 
for 4 h. After work-up the precipitate was washed with ether: yellow 
crystals. The yields ranged from 65 to 75 %. 
5\6-Dihydro-3,9-dimethoxy-l2,12-dimethyl-indolo/'2,1-a/isoquinolinium 
iodide (3b) 
M . p. 220° dec. - C 2 0 H 2 2 N O 2 • I x H 2 0 (453.3) Vale. C 53.1 H 4.86 
Found C 53.0 H 4.89. - IR (KBr) : 3450 ( H 2 0 ) , 1630 (C=N) cn r 1 . - lH-
N M R (90 M H z ) : 5 (ppm) = 1.87 (s; 6 H , - C H 3 ) , 3.64 (t; J = 7 Hz , 2 H , 
- C H 2 - ) , 4.0 (s; 3 H , - O C H 3 ) , 4.04 (s; 3 H , - O C H 3 ) , 4.97 (t; J - 7 Hz , 2 H , 
- C H 2 - ) , 7.03-7.23 (m; 3 H , A r H ) , 7.47 (d; J = 9 H z , 1H, A r H ) , 7.54 (s; 
1H, A r H ) , 8.16 (d; J = 9 H z , 1H, A r H ) . 
5,6-Dihydro-3,9,10-trimethoxy-l 2,12-dimethyl-indolo/2,1 -a /isoquinoli-
nium iodide (3c) 
M . p. 226° dec. - C 2 1 H 2 4 N 0 3 • I x H 2 0 (483.3) Calc. C 52.2 H 5.00 
Found C 51.7 H 5.08. - ' H - N M R : 5 (ppm) = 1.88 (s; 6 H , - C H 3 ) , 3.58 (t; 
J = 7 H z , 2 H , - C H 2 - ) , 4.0 (s; 6 H , - O C H 3 ) , 4.13 (s; 3 H , - O C H 3 ) , 5.0 (t; 
J = 7 H z , 2 H , - C H 2 - ) , 7.0-7.17 (m; 3 H , A r H ) , 7.67 (s; 1H, A r H ) , 8.1 (d; 
J = 9 H z , 1H, A r H ) . - U V (MeOH): X max (log e) = 434 (4.19), 308 
(3.75), 247 (4.33) nm. 
5,6-Dihydro-2,3,10-trimethoxy-l 2,12-dimethyl-indolo/2,1 -a/isoquinoli-
nium iodide (3d) 
M . p. 240° dec. - C 2 1 H 2 4 N 0 3 • I x H 2 0 (483.3) Calc. C 52.2 H 5.00 
Found C 51.5 H 4.94. - J H - N M R : 5 (ppm) = 1.93 (s; 6 H , - C H 3 ) , 3.66 (t; 
J = 7 H z , 2 H , - C H 2 - ) , 3.93 (s; 3H, - O C H 3 ) , 4.0 (s; 3 H , - O C H 3 ) , 4.13 (s; 
3 H , - O C H 3 ) , 4.91 (t; J = 7 Hz , 2 H , - C H 2 - ) , 7.03-7.27 (m; 3 H , A r H ) , 
7.43 (s; 1H, A r H ) , 7.87 (d; J = 9 H z , 1H, A r H ) . 
5,6-Dihydro-2,3,9-trimethoxy-l2,12-dimethyl-indolo/2,1 -a /isoquinoli-
nium iodide (3e) 
M . p. 210-211° dec. - C 2 1 H 2 4 N 0 3 • I x H 2 0 (483.3) Calc. C 52.2 H 5.00 
Found C 51.9 H 5.16. - ' H - N M R : 5 (ppm) = 1.85 (s; 6 H , - C H 3 ) , 3.63 (t; 
J = 7 H z , 2 H , - C H 2 - ) , 3.96 (s; 6 H , - O C H 3 ) , 4.08 (s; 3 H , - O C H 3 ) , 4.97 
(t; J - 7 H z , 2 H , - C H 2 - ) , 7.0 (dd; J 1 / 2 = 8/2 H z , 1H, A r H ) , 7.23 (s; 1H, 
A r H ) , 7.3 (d;J = 8 H z , 1H, A r H ) , 7.36 (s; 1H, A r H ) , 7.47 (d; J = 2 H z , 
1H, A r H ) . 
5,6-Dihydro-2,3,9,10-tetramethoxy-l 2,12-dimethyl-indolo/2,1 -a/isoqui-
nolinium iodide (3f) 
M . p. 232° dec. - C 2 2 H 2 6 N 0 4 • I x H 2 0 (512.3) Calc. C 51.5 H 5.10 
Found C 51.0 H 5.51. - ' H - N M R : 6 (ppm) = 1.89 (s; 6 H , - C H 3 ) , 3.59 (t; 
J = 7 H z , 2 H , - C H 2 - ) , 4.0 (s; 6 H , - O C H 3 ) , 4.09 (s; 3 H , - O C H 3 ) , 4.12 (s; 
3 H , - O C H 3 ) , 5.03 (t; J = 7 Hz , 2 H , - C H 2 - ) , 7.09 (s; 1H, A r H ) , 7.17 (s; 
1H, A r H ) , 7.4 (s; 1H, A r H ) , 7.67 (s; 1H, A r H ) . 
General Procedure for the Synthesis of 12-Formyl-5,6-dihydro-indolo-
[2,1-aJisoquinolines 4a-f 
Absol . D M F (0.6 ml) was added slowly to P O C l 3 (0.9 ml) at 10-20° under 
N 2 . The mixture was stirred for 5 min at 15-20° The 5,6-dihydro-metho-
xy-indolo[2,l-alisoquinoline (1.0 mmol) dissolved in 5 ml absol. D M F 
was added slowly to keep the temp, below 35°. After stirring for 35 min at 
35°, the mixture was poured into 30 ml ice water. The aqueous layer was 
basified (NaOH), and extracted with C H C 1 3 . After washing with water 
and drying ( N a 2 S 0 4 ) , the solvent was removed in vacuo. The products 
were recrystallized from M e O H to give slightly yellow crystals. The yields 
were 70-90 %. 
12-Formyl-5,6-dihydro-3,10-dimethoxy-indolo[ 2,1-a/isoquinoline (4a) 
M . p. 160.5°. - C 1 9 H 1 7 N 0 3 (307.3) Calc. C 74.3 H 5.57 Found C 74.2 
H 5.69. - IR (KBr) : 1640 (CO) cm- 1 . - ^ - N M R (90 M H z ) : 5 (ppm) = 
3.13 (t; J = 7 H z , 2 H , - C H 2 - ) , 3.88 (s; 3 H , - O C H 3 ) , 3.93 (s; 3 H , 
- O C H 3 ) , 4.2 (t; J = 7 H z , 2 H , - C H 2 - ) , 6.91 (s; 1H, A r H ) , 6.95, 7.27 ( A B ; 
J = 9 H z , 2 H , A r H ) , 6.96 (d; J = 9 H z , 1H, A r H ) , 7.85 (d; J = 2 Hz , 1H, 
A r H ) , 7.9 (dd; J 1 / 2 = 9/2 H z , 1H, A r H ) , 10.5 (s; 1H, - C H O ) . - U V 
( C H 3 C N ) : X max (log e) = 350 (4.36), 272 (4.47) nm. 
12-Formyl-5,6-dihydro-3,9-dimethoxy-indolol 2,1-a/isoquinoline (4b) 
M . p. 170.5°. - C 1 9 H 1 7 N 0 3 (307.3) Calc. C 74.3 H 5.57 Found C 74.3 
H 5.59. - * H - N M R (90 M H z ) : 8 (ppm) = 3.1 (t; J = 7 Hz , 2 H , - C H 2 - ) , 
3.87 (s; 6 H , - O C H 3 ) , 4.12 (t; J = 7 H z , 2 H , - C H 2 - ) , 6.73-7.0 (m; 4 H , 
A r H ) , 7.83 (d;J = 9 H z , 1H, A r H ) , 8.23 (d; J = 9 H z , 1H, A r H ) , 10.42(s; 
1H, - C H O ) . 
12-Formyl-5,6-dihydro-3,9,10-trimethoxy-indolol 2,1-a/isoquinoline (4c) 
M . p. 161.5°. - C 2 0 H 1 9 N O 4 (337.3) Calc. C 71.2 H 5.67 Found C 71.3 
H 5.56. - ^ - N M R : 8 (ppm) = 3.12 (t; J = 7 H z , 2 H , - C H 2 - ) , 3.88 (s; 3 H , 
- O C H 3 ) , 3.97 (s; 3 H , - O C H 3 ) , 4.0 (s; 3H , - O C H 3 ) , 4.14 (t; J = 7 Hz , 2 H , 
- C H 2 - ) , 6.76-6.99 (m; 3H, A r H ) , 7.70-7.95 (m; 2 H , A r H ) , 10.4 (s; 1H, 
- C H O ) . 
12-Formyl-5,6-dihydro-2,3,10-trimethoxy-indolol2,1-a/isoquinoline (4d) 
M . p. 212°. - C 2 0 H 1 9 N O 4 (337.3) Calc. C 71.2 H 5.67 Found C 71.4 
H 5.68. - * H - N M R (90 M H z ) : 5 (ppm) = 3.09 (t; J = 7 Hz , 2 H , - C H 2 - ) , 
3.90 (s; 3 H , - O C H 3 ) , 3.94 (s; 3 H , - O C H 3 ) , 3.97 (s; 3H , - O C H 3 ) , 4.16 (t; 
J = 7 H z , 2 H , - C H 2 - ) , 6.8 (s; 1H, A r H ) , 6.87 (dd; J 1 / 2 = 9/2 Hz , 1H, 
A r H ) , 7.20 (d; J = 9 Hz , 1H, A r H ) , 7.53 (s; 1H, A r H ) , 7.84 (d; J = 2 H z , 
1H, A r H ) , 10.47 (s; 1H, - C H O ) . 
12-Formy 1-5,6-dihydro-2,3,9-trimethoxy-indolo/2,1-a/isoquinoline (4e) 
M . p. 208°. - C 2 0 H 1 9 N O 4 (337.3) Calc. C 71.2 H 5.67 Found C 70.8 
H 5.76. - ' H - N M R (90 M H z ) : 5 (ppm) = 3.09 (t; J = 7 H z , 2 H , - C H 2 - ) , 
3.87 (s; 3 H , - O C H 3 ) , 3.97 (s; 6 H , - O C H 3 ) , 4.14 (t; J = 7 H z , 2 H , 
- C H 2 - ) , 6.84-6.9 (m; 2 H , A r H ) , 6.93 (dd; J 1 / 2 = 9/2 H z , 1H, A r H ) , 7.58 
(s; 1H, A r H ) , 8.23 (d; J = 9 H z , 1H, A r H ) , 10.51 (s; 1H, - C H O ) . 
12-Formyl-5,6-dihydro-2,3,9,10-tetramethoxy-indolol 2,1-a/isoquinoline 
(4f) 
M . p. 217.5°. - C 2 1 H 2 1 N O s (367.4) Calc. C 68.7 H 5.72 Found C 68.3 
H 5.85. - ^ - N M R : 5 (ppm) = 3.1 (t; J = 7 H z , 2 H , - C H 2 - ) , 3.98 (s; 12H, 
- O C H 3 ) , 4.17 (t; J = 7 H z , 2 H , - C H 2 - ) , 6.8 (s; 1H, A r H ) , 6.83 (s; 1H, 
A r H ) , 7.5 (s; 1H, A r H ) , 7.9 (s; 1H, A r H ) , 10.5 (s; 1H, - C H O ) . 
2,3,9,10-Tetramethoxy-12-methyl-indolol2,1-a/isoquinoline (5) 
2f (1.3 mmol) and Pd/C 10 % (150 mg) were mixed thoroughly in an agate 
mortar. This and all of the following operations were carried out under N 2 . 
A flask containing the mixture was placed in an oil bath of a temp, which 
was kept 10-15° above the melting point of the dihydro compound. After 
30 min, the mixture was stirred with a spatula. Heating was continued for 
30 min. After cooling, the mixture was dissolved in C H 2 C 1 2 and filtered. 
The solvent was evaporated. Recrystallization from E t O H afforded yel-
low crystals. - Yield 15 %; m. p. 230° dec. - C 2 1 H 2 1 N 0 4 x 1/4 H 2 0 
(355.4) Calc. C 71.8 H 6.02 Found C 71.8 H 6.03. - IR (KBr) : 3420 
( H 2 0 ) cm- 1 . - • H - N M R : 8 (ppm) = 2.76 (s; 3 H , - C H 3 ) , 3.93 (s; 3 H , 
- O C H 3 ) , 3.96 (s; 3 H , - O C H 3 ) , 4.01 (s; 3 H , - O C H 3 ) , 4.03 (s; 3 H , 
- O C H 3 ) , 6.50, 7.83 ( A B ; J = 9 H z , 2 H , A r H ) , 6.82 (s; 1H, A r H ) , 6.97 (s; 
1H, A r H ) , 7.2 (s; 1H, A r H ) , 7.8 (s; 1H, A r H ) . - M S : m/z = 351 (100 %, 
M+-), 336 (60 %, *321.64), 175.5 (15.%, M^/2). - U V ( C H 3 C N ) : X max 
(log 6) = 372 (3.99), 353 (4.05), 319 (4.49), 306 (4.34), 280 (4.57) nm. 
12-Formyl-2,3,9,10-tetramethoxy-indolof2,1-a/isoquinoline (6) 
6 was synthesized from 4f according to the procedure described above. 
Recrystallization from M e O H afforded yellow crystals. - Yield 50 %; 
m. p. 281°. - C 2 1 H 1 9 N 0 5 x 1/2 H 2 0 (374.4) Calc. C 67.4 H 5.38 Found 
C 67.4 H 5.49. - IR (KBr) : 3420 ( H 2 0 ) , 1630 (CO) cm" 1 . - ! H - N M R 
(250 M H z ) : 5 (ppm) = 4.03 (s; 3 H , - O C H 3 ) , 4.04 (s; 3H , - O C H 3 ) , 4.06 
(s; 3H , - O C H 3 ) , 4.14 (s; 3 H , - O C H 3 ) , 7.04, 8.05 ( A B ; J = 9 Hz , 2 H , 
A r H ) , 7.07 (s; 1H, A r H ) , 7.20 (s; 1H, A r H ) , 7.27 (s; 1H, A r H ) , 7.87 (s; 
1H, A r H ) , 10.68 (s; 1H, - C H O ) . - M S : m/z = 365 (100 %, M+-), 350 
(79 %, *335.61), 335 (5 %), 182.5 (14 %, M 2 + / 2 ) . - U V ( C H 3 C N ) : X max 
(log e) = 409 (4.32) 387 (4.21), 366 (3.97), 293 (4.35), 259 (4.50) nm. 
General Procedure for the Ether Cleavage and Acetylation 
0.3 mmol of the methoxysubstituted indoloisoquinoline in 5 ml absol. 
C H 2 C 1 2 was cooled to - 1 5 ° under N 2 and B B r 3 (0.1 ml) was added. After 
stirring for 30 min. the cooling bath was removed and the mixture was stir-
red for 15 h. With cooling, the mixture was poured into 10 ml of an aqueous 
solution of N a H C 0 3 . Then 25 ml E t O A c were added and the mixture was 
stirred for 15 min. The org. layer was separated, and the aqueous phase 
was extracted with E t O A c . The combined org. layers were washed with 
saline and dried ( N a 2 S 0 4 ) . After the solvent was removed, the dark resi-
due was treated with 6 ml A c 2 0 and 1 ml pyridine. After refluxing for 2 h, 
the mixture was poured onto ice, stirred for 10 min and extracted with 
C H 2 C 1 2 . The org. layer was washed with water and dried ( N a 2 S 0 4 ) . After 
evaporation, the remaining residue was chromatographed (S iO z ; C H 2 C 1 2 ) 
or was crystallized with M e O H at 3°. Recrystallization from E t O H or 
M e O H yielded colorless crystals. 
3,9-Diacetoxy-5,6-dihydro-l2-methyl-indolol'2,1-a/isoquinoline (7) 
7 was synthesized from 2b. Yield 80 %; m. p. 157°. - C 2 1 H 1 9 N 0 4 (349.4) 
Calc. C 72.2 H 5.48 FoundC 71.9 H 5.59. - IR (KBr) : 1760 (CO) c m - 1 . -
! H - N M R (90 M H z ) : 5 (ppm) - 2.33 (s; 6 H , - O C O C H 3 ) , 2.60 (s; 3 H , 
- C H 3 ) , 3.12 (t; J - 7 H z , 2 H , - C H 2 - ) , 4.17 (t; J = 7 H z , 2 H , - C H 2 - ) , 6.86 
(dd; J1/2 = 9/2 Hz , 1H, A r H ) , 7.11 (s; 2 H , A r H ) , 7.13 (dd; J 1 / 2 = 9/2 Hz , 1H, 
A r H ) , 7.6 (d; J = 9 H z , 1H, A r H ) , 7.88 (d; J = 9 Hz , 1H, A r H ) . 
3,9-Diacetoxy-12-formyl-5,6-dihydro-indolol2,1-a/isoquinoline (8) 
8 was synthesized from 4b. Yield 80 %; m. p. 165°. - C 2 1 H 1 7 N O s (363.4) 
Calc. C 69.4 H 4.71 Found C 69.6 H 4 . 5 5 . - I R ( K B r ) : 1 7 6 0 ( O C O C H 3 ) , 
1640 ( C H O ) c m 1 . - * H - N M R (90 M H z ) : 8 (ppm) = 2.37 (s; (>H, 
- O C O C H 3 ) , 3.16 (t; J - 7 H z , 2 H , - C H 2 - ) , 4.2 (t; J = 7 Hz , 2 H , - C H 2 - ) , 
6.9-7.28 (m; 4 H , A r H ) , 8.0 (d; J = 9 H z , 1H, A r H ) , 8.43 (d; J = 9 H z , 1H, 
A r H ) , 10.52 (s; 1H, - C H O ) . 
2,3,9,10-Tetraacetoxy-12-formyl-5,6-dihydro-indolol 2,1-a/isoquinoline 
(9) 
9 was synthesized from 4f. Yield 80 %; m. p. 259°. - C 2 5 H 2 1 N 0 9 (479.4) 
Calc. C 62.6 H 4.41 Found C 62.0 H 4.20. - I R ( K B r ) : 1775 ( O C O C H 3 ) , 
1645 ( C H O ) cm- 1 . - ' H - N M R (CDC1 3 ) : 8 (ppm) = 2.37 (s; 12H, 
- O C O C H 3 ) , 3.18 (t; J = 7 Hz , 2 H , - C H 2 - ) , 4.27 (t; J = 1 Hz , 2 H , 
- C H 2 - ) , 7.37 (s; 2 H , A r H ) , 7.97 (s; 1H, A r H ) , 8.37 (s; 1H, A r H ) , 10.62 
(s; 1H, - C H O ) . 
Biological Methods 
MCF-7 Human Breast Cancer Cells5>> 
The M C F - 7 cell line was kindly provided by Dr . M. E. Lippman, N C I , 
Bethesda, M D , U S A . Cells were grown in improved minimal essential me-
dium ( M E M ) , as modified by Richter et al.6> (Biochrom, Berlin), supple-
merited with glutamine (0.3 g/L), gentamycin (60 mg/L), and 5 % new-
born calf serum'(NCS) (Gibco) or charcoal-treated N C S (CCS). C C S was 
prepared by incubation of 500 ml of N C S with a dextran-coated charcoal 
pellet7 ) for 4 h in a shaker at 4 -0° . The procedure was repeated with a fresh 
pellet. After each incubation, the charcoal was removed by centrifugation. 
The serum was filtered through a 0.20 urn filter (Sartorius) and stored at 
-20° . Cells were grown in a humidified incubator in 5 % C 0 2 at 37° Two 
weeks before start of the experiment, cells were switched from N C S to. 
C C S and received two additional media changes before they were harvest-
ed with 0.05 % trypsine - 0.02 % E D T A in 0.15 M N a C l . They were sy-
ringed gently to prevent clumping, and approximately 2 x 10 4 cells in 2 ml 
were plated replicately in sixwell dishes (Costar). One day later, cells were 
switched to a medium containing the substances and 0.1 % ethanol in 
which the compounds had been dissolved. The medium of control wells 
contained an equal volume of ethanol. A t the fourth day, media were 
changed and substances added again. Three days later, cells were labeled 
with 1 uC of [ 3H]thymidine/well for 2 h. Cells were washed with cold PBS 
and harvested in PBS containing 0.02 % E D T A . After centrifugation, the 
cell pellet was resuspended in 1 ml of PBS and divided in two equal parts. 
One part was counted in a Z M Coulter counter; the other one was sonica-
ted. After addition of 4 ml of 10 % trichloroacetic acid, the acid-insoluble 
fraction was collected on a 0.45 urn filter (Sartorius) and counted after ad-
dition of 10 ml of scintillation liquid (Quickszint 212, Zinsser) in a L S 
1801 Beckman scintillation counter. 
MDA-MB 231 Human Breast Cancer Cells 
The M D A - M B 231 cell line was also provided by Dr . M. E. Lippman. 
Cells were grown in a McCoy 5a medium (Boehringer Mannheim) supple-
mented with 10 % N C S and gentamycin (40 ug/ml). The experiments 
were performed as described for the M C F - 7 cells with one exception: the 
incubation period was reduced from 6 to 2 days. 
P388 D1 Leukemia Cells 
The experimental details for the tests with P388 D.j leukemia cells have 
been described1). 
P388 Leukemia of the Mouse 
P388 leukemia cells were generously provided by Dr . ^4. E. Bogden, E G 
& G Mason Research Institute, Worcester, M A , U S A . The tumor cells 
grow as ascites in the abdominal lumen of female D B A / 2 mice (Charles-
River-Wiga, Sulzfeld). After one week, the ascites is removed with a sy-
ringe and diluted with sterile icecold PBS to reach a cell number of 10 7 
cells/ml. 0.1 ml of this cell suspension is injected ip. into 6-10 weeks old 
animals. Female CDFj-mice were used for the determination of the cyto-
static activity of drugs. After the ip. injection of 10 6 cells at day 0, the ani-
mals were randomized into groups of six. 24 h later (day 1), and at day 
5 and 9 compounds dissolved or suspended in polyethylene glycol 
400/0.9 % saline (1:1) were administered (0.2 ml/animal). Control ani-
mals received only the solvent. 
Survival time was recorded daily. A t day 1 and 5, the body weights were 
determined. The median survival time of treated animals was compared 
with that of the control group and the result is expressed as % T / C . The de-
crease of body weight between day 1 and day 5 compared with control 
animals was used as parameter for an acute toxicity of the drugs. 
Estradiol Receptor Binding Assay®* 
The relative binding affinity (RB A ) of the test compounds was deter-
mined in a competitive binding assay with f 3H]estradiol. Cal f uterine cyto-
sol was incubated for 18 h at 4° with different cone, of competitor and 5 x 
10~9 M [ 3Hlestradiol. After incubation, dextran-coated charcoal was ad-
ded to absorb unbound ligand (90 min, 4°) and, after centrifugation, ra-
dioactivity was determined in the supernatant using 100 ul aliquots. Six 
concentrations of competitor were chosen to provide values between 10 
and 90 % bound radioactivity. A semilogarithmic plot of bound radioacti-
vity versus concentration was used to determine the relative binding affini-
ty given as ratio of molar concentration of estradiol and test compound re-
quired to decrease the amount of bound radioactivity by 50 %, multiplied 
with 100. 
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